interleukin-4 PE38KDEL cytotoxin

Phase 2Biologic

Neurocrine Biosciences

interleukin-4 PE38KDEL cytotoxin is one of 95 biologic programs targeting Astrocytoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AstrocytomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Glioblastoma MultiformeActive, not recruiting

AstrocytomaPhase 1

Active, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Glioblastoma MultiformePhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

PORTRAZZA

Eli Lilly

Preclinical

8 2

Vizimpro

Pfizer

Preclinical

4 3

Gilotrif

Boehringer Ingelheim

Preclinical

12 4

interleukin-4 PE38KDEL cytotoxin

Neurocrine Biosciences

Phase 2

1 5

Ofev

Boehringer Ingelheim

Preclinical

7 6

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 8

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 9

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—10

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Glioblastoma Multiforme1 trial

NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma Multiforme

Completed· Neurocrine Biosciences logo

Neurocrine Biosciences·Phase 2·NCT00014677

Non-Small Cell Lung Cancer1 trial

Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast Cancer

Completed· Neurocrine Biosciences logo

Neurocrine Biosciences·Phase 1·NCT00039052

Astrocytoma1 trial

IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma

Unknown status·—·Phase 1·NCT00003842·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for interleukin-4 PE38KDEL cytotoxin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — interleukin-4 PE38KDEL cytotoxin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for interleukin-4 PE38KDEL cytotoxin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Neurocrine Biosciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: Neurocrine Biosciences

interleukin-4 PE38KDEL cytotoxin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Glioblastoma Multiforme1 trial

Non-Small Cell Lung Cancer1 trial

Astrocytoma1 trial

References

Drug Info

Quick Facts

Related News